Approval of Tisotumab Vedotin in The Treatment of Cervical Cancer

Expert gynecologic oncologist Rebecca Arend, MD, MPH, addresses data from the 2021 ESMO meeting and the approval of tisotumab vedotin for patients with cervical cancer.

EP. 1: Evolving Therapy in Cervical Cancer: Tisotumab Vedotin’s Mechanism of Action

November 1st 2021

A historical perspective on the management of recurrent or metastatic cervical cancer, followed by expert insight on tisotumab vedotin’s mechanism of action.

EP. 2: InnovaTV 204 Trial in Cervical Cancer: Study Design and Key Efficacy Results

November 1st 2021

Rebecca Arend, MD, MPH, reviews the study design and results from innovaTV 204, which tested tisotumab vedotin in previously treated, recurrent, or metastatic cervical cancer.

EP. 3: Interim Results of the InnovaTV 205 Trial in Cervical Cancer

November 1st 2021

Considerations for the interim results of innovaTV 205, which tested tisotumab vedotin alone or in combination with other agents for patients with cervical cancer.

EP. 4: FDA Approval of Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

November 1st 2021

A brief review of the FDA approval and implications of tisotumab vedotin in patients with recurrent or metastatic cervical cancer.

EP. 5: The Future Management of Cervical Cancer: Novel Agents and Clinical Pearls for Community Onclogists

November 1st 2021

Rounding out her discussion on the use of tisotumab vedotin in cervical cancer, Rebecca Arend, MD, MPH, considers other agents being investigated and how that may impact the future treatment landscape.